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INTRODUCTION 
 
 
 
 
 
Ventilator Associated Pneumonia ( VAP) is defined as pneumonia that occurs 
in a patient after 48 hours of intubation. It is associated with high morbidity , 
mortality, prolonged hospital stay, and cost of treatment.  It was said that 3% 
of the intubated patients get VAP every  day in the first 5 days. Late onset 
VAP , ie VAP that occurs after 5 days of intubation is usually caused by multi-
drug resistant pathogens , and it is associated with higher mortality . 
  
    The purpose of the study is to determine the clinical profile, microbiological 
profile, predictive factors of the outcome of VAP and the incidence of VAP. 
The study consists of collection of demographic details, clinical details, 
assessment of CPIS score, APACHE-II score, MOD Score, follow up of 
endotracheal aspirate/ bronchial wash/ bronchoalveolar lavage culture reports 
and procalcitonin levels of patient who develop VAP in Medical and Surgical 
ICU and HDUs and Respiratory Medicine HDU. Those patients will be 
followed up throughout their hospital stay till discharge to analyze the 
outcome and mortality. The findings in various ICUs will be compared. 
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AIM 
 
 
To determine the clinical profile, microbiological profile and the predictive factors of 
the outcome in Ventilator Associated Pneumonia. 
 
 
 
 
 
 
OBJECTIVES 
 
 
1. To study the clinical profile of VAP in Indian ICUs and HDUs. 
2.  To describe the microbiologic profile of VAP.  
 3,  To find out the difference in the microbiologic profile  amongst different ICUs/HDUs in 
the same hospital. 
 4,  To find out the prevalence of MDR organisms in VAP. 
5,  To find out the predictive value of the following at diagnosis towards outcome and 
prognosis. 
- Modified CPIS Score 
 - APACHE-II Score 
- Multiple Organ Dysfunction Score 
 - Serum Procalcitonin level 
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REVIEW OF LITERATURE 
 
 
DEFINITION 
 
  Ventilator Associated Pneumonia (VAP) is defined as pneumonia developing 48 
hours after intubation, in a patient in whom, there was no signs of symptoms of lung 
infection at the time of intubation.   
VAP is caused by the microbiological invasion of the lower respiratory tract and the 
lung parenchyma. Endo-tracheal intubation and mechanical ventilation compromises 
the first line of defence against the microbiological invasion by disrupting the integrity 
of the oro-pharynx and the airways. 
 
EPIDEMIOLOGY 
 
 
Ventilator Associated Pneumonia (VAP) is one of the most common adverse event 
seen in mechanically ventilated patients in ICUs throughout the world.  About 28% of 
the intubated patients get VAP during there intubated days. There are various studies 
looking at the incidence of VAPs all over the world and it ranges from 3% to 30%.  
The risk of developing VAP will keep on increasing when the number of intubation 
days progresses. For the first 5 days, the rate of incidence of VAP is 3% per day. Later 
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it decreases to 2% per day for the next 5 days, thereafter it is assumed to be 1% per 
day  (1).    VAP is considered to be one of the most common infection in ventilated 
patients in ICUs  with an incidence of  6-52 % (2) . VAP is associated with increased 
hospital and ICU stay. Overall attributable mortality of VAP was estimated to be 
around 9% (3) . In 1974, studies showed 50% mortality in VAP patients when 
mortality among other ICU patients was only 4% (4). 
     In another study, it was showed that VAP will prolong the duration of mechanical 
ventilation from 10 to 32 days (5). In another study , the median duration of stay in the 
ICU for the patients with VAP was 21 days and a median of 15 days was observed for 
paired control subjects (6). A mean prolongation of ICU stay of 20 days was observed 
in patients with VAP when surviving pairs were compared. Reported mean durations 
of mechanical ventilation, ICU stay, and hospital stay were, respectively, 12.0, 20.5, 
and 43.0 days for trauma patients with pneumonia compared with 8.0, 15.0, and 34.0 
days for their matched control subjects (7). 
 
Postsurgical patients are at a high risk for VAP. It accounts for about one-third of the 
pulmonary infiltrates in the ICU patients (8) . In a 1981 study, the VAP rate during the 
postoperative period was 17%  (9). The development of pneumonia was associated 
with serum  markers of severity of the primary disease, like low serum albumin. The 
history of cigarette smoking, longer hospital stay before surgery, long intra-operative 
period, and thoracic or upper abdominal interventions were also found to be important 
risk factors for post-operative pneumonia. Another comparative study on various adult 
ICUs demonstrated that postsurgical patients had consistently higher rates of 
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ventilator associated pneumonia than medical ICU patients, with a RR of 2.2 (6). 
 
This throws light to the importance of early detection and adequate management in the 
intensive care units.  
 
 
 
TYPES OF VAP  
a, Early VAP 
b, Late VAP 
 
VAP which develops within the first 4 days of intubation was called as Early VAP , 
and those which develop after 4 days was considered as Late VAP.  They are found to 
be different from each other in various aspects, such as mortality, days of hospital 
stay,  microbiological organisms involved,  morbidity and other complications.  In a 
prospective study done in JIPMER, Pondichery, following up the patients admitted in 
various ICUs for a period of 15 months found out that, 36 (18%) out of 200 intubated 
patients  developed VAP. Of these, 41.7% of VAP was early onset and there was a 
higher incidence of VAP in MICU when compared to CCU (10). Early onset VAP is 
usually less severe and they are caused by antibiotic sensitive micro organisms. So 
they have a better prognosis. Late onset VAP is usually caused by Multi drug resistant 
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organisms and it is associated with high rate of mortality. 
 
RISK FACTORS 
 
There are various risk factors that predispose a patient to develop Ventilator 
Associated Pneumonia.  They can be grossly classified into - 
1, Host related 
2, Healthcare personnel related 
and 
3, Device related 
 
HOST RELATED 
a, Level of consciousness 
b, Underlying immunosuppression 
- Infection (eg. HIV) 
- Drugs (eg. Chemotherapy) 
- Other co-morbidities (eg. Diabetes Mellitus) 
c, Chronic obstructive lung disease 
d, Acute respiratory distress syndrome 
e, Body positioning of the patient 
 
HEALTH PERSONNEL RELATED 
a, Poor hand hygiene 
b, Not changing gloves after seeing another patient 
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c, Not wearing aprons and hair cap 
d, Not using hand rub 
c, Carriers of resistant organisms in the next bed 
 
DEVICE RELATED 
a, Unhygienic method of intubation 
b, Unhealthy surroundings during intubation 
c, Nasogastric and oro-gastric tube 
d, Recurrent change of ventilatory circuits 
e, Contaminated ventilatory tubings 
 
 
PATHOGENESIS 
 
Normal defense mechanisms in the human respiratory system 
The normal defense mechanism in the human respiratory system consists of 
a,  Anatomy of the human airway 
b, Mucus 
c, Basement membrane 
d, Cough reflex 
e, Muco-ciliary system 
f, Lactoferrin 
g, Leukocytes 
h, Alveolar macrophages 
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g, Immunoglobulins 
h, Complements 
 
Pathway for micro-organisms to reach the lungs 
a, Aspiration of the oro-pharyngeal contents 
b, Stomach contents reaching the lower respiratory tract by reflux and then getting 
aspirated 
c, Inhalation of the infected chemical fumes and aerosols 
d, Direct spread of infection from the pleural space 
e, Hematogenous spread of the infection to the lungs 
Micro-aspirations are considered to be the most common cause of infection. 
The normal flora of our oropharynx consists of Streptococcus viridians, Haemophilus 
species and anaerobic organisms.  When critically ill, a aerobic gram negative bacilli 
and staphylococcus aureus predominance develop.  
Change in the orotracheal mucosa which helps in bacterial adherence in critically ill 
patients include- 
a,  Increased protease production 
b, Denuded and exposed mucosa 
c, Reduced immunoglobulin -A, one of the predominant host defense in the mucosa 
d, Elevated pH of the airways 
e, Increase in the receptors of the airway for the bacteria 
The critical illness as well as the antimicrobial usage play a predominant role in 
establishment of these changes (11).  
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The stomach contents reaching the lower airways as a result of reflux mechanism and 
then getting aspirated to the distal airways is one of the predominant mechanism in the 
development of VAP.  The use of antacids, which is a part of ulcero-prophylaxis in the 
intubated patients in the Intensive Care Units , can lead to increase in the gastric acid 
pH and thus the proliferation of the bacteria in the stomach. So once aspirated there is 
higher chance for this aspirate to cause an active infection in the lower airways in 
comparison with those who are not on any antacids (12). The immobilization of the 
patient and absence of gastric feeding will add on to this. 
 
 
 
 
 
 
 
 
 
 
 
Table A- Source of outbreak and the common organisms found based on various 
studies 
(Adapted from 'Nasia Safdar CJC. The pathogenesis of ventilator-associated 
pneumonia: its relevance to developing effective strategies for prevention.') 
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Biofilms formed inside the endo-tracheal tube can also act as a reservoir of infective 
organisms. It is resistant to the antibiotics and the various defence mechanisms of our 
body.  
 
- CLINICAL SYMPTOMS 
VAP characterisrically presents with - 
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A, A  new or worsening lung opacities in the chest x ray 
B, Fever  
C, Purulent tracheobronchial secretions 
D, Leukocytosis 
E, Tachypnoea 
F, Decreased tidal volume 
G, Increased minute ventilation 
H, Hypoxia (13) 
On respiratory system examination, following findings can be observed 
-  Asymmetric ronchi (due to the secretions) 
-  Crackles 
-  Decreased breathsounds 
-  Bronchospasm 
-  Hemoptysis 
Deterioration in the patient's condition in terms of the oxygenation and ventilator 
requirements can be the first sign of development of Ventilator Associated 
Pneumonia. 
 
EVALUATION AND DIAGNOSIS 
 
There are various criteria used in the diagnosis of VAP. European literature uses 
HELICS criteria for the diagnosis of VAP.   
A, Hospitals in Europe Link  for Infection Control through Surveillance (HELICS) 
criteria (14) 
• Positive radiology  
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2 or more serial chest X-rays or CT scans with a image of pneumonia for patients 
those who have an underlying cardiac or pulmonary disease. In patients those who 
have underlying cardiac or pulmonary disease, only one definitive chest X-ray or CT-
scan is enough. 
• Fever > 38 ˚C and no other causes for the fever 
• Leukopenia (<4000 WBC/mm3) or leucocytosis (≥ 12 000 WBC/mm3)  
and at least anyone of the following (or at least two if clinical pneumonia only = PN 4 
and PN 5) 
• New onset of purulent sputum, or change in character of sputum (colour, odour, 
quantity, consistency)  
• Cough or dyspnoea or tachypnoea 
• Suggestive auscultation (rales or bronchial breath sounds), rhonchi, wheezing  
• Worsening gas exchange (e.g., O2 desaturation or increased oxygen requirements or 
increased ventilation demand) 
 
a – Bacteriologic diagnostic performed by:  
Positive quantitative culture from minimally contaminated LRT1 
 specimen 
• Broncho-alveolar lavage (BAL) with a threshold of ≥ 104 cfu/mL or ≥ 5 % of BAL 
obtained cells contains intracellular bacteria on direct microscopic exam (classified on 
diagnostic category BAL).  
• Protected brush (PB Wimberley) with a threshold of ≥ 103 cfu/mL 
• Distal protected aspirate (DPA) with a threshold of ≥ 103 cfu/mL  -  PN1 
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Positive quantitative culture from possibly contaminated LRT specimen 
Quantitative culture of LRT specimen (e.g., endotracheal aspirate) with a threshold of 
106 cfu/mL   - PN2 
b- Alternative microbiology methods  
• Positive blood culture not related to another source of infection  
• Positive growth in culture of pleural fluid  
• Pleural or pulmonary exam shows evidence of pneumonia  
• Positive exams for pneumonia with virus or particular germs (Legionella, 
Aspergillus, mycobacteria,  
Mycoplasma, Pneumocystis carinii)  
• Positive detection of viral antigen or antibody from respiratory secretions (e.g., EIA, 
FAMA,  
shell vial assay, PCR)  
• Positive direct exam or positive culture from bronchial secretions or tissue  
• Seroconversion (ex: influenza viruses, Legionella, Chlamydia)  
• Detection of antigens in urine (Legionella) -   PN3 
c-Others 
Positive sputum culture or non-quantitative LRT specimen culture - PN4 
No positive microbiology -  PN5 
B,  Modified CDC criteria for diagnosis of VAP (15) 
 
RADIOLOGICAL - 
Two or more serial chest radiographs with at least one of the following:  
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 • New or progressive and persistent infiltrate  
 • Consolidation  
 • Cavitation  
In patients without underlying pulmonary or cardiac disease (e.g., respiratory distress 
syndrome, bronchopulmonary dysplasia, pulmonary edema, or chronic obstructive 
pulmonary disease), one definitive chest radiograph is acceptable 
 
SIGNS/ SYMPTOMS/ LABORATORY - 
 
For ANY PATIENT, at least one of the following:  
 • Fever (>38°C or >100.4°F)  
• Leukopenia (<4000 WBC/mm3) or leukocytosis (>12,000 WBC/mm3)  
• For adults >70 years old, altered mental status with no other recognized cause  
 and at least two of the following:  
 • New onset of purulent sputum, or change in character of sputum, or increased  
   respiratory secretions, or increased suctioning requirements  
• New onset or worsening cough, or dyspnea, or tachypnea 
• Rales or bronchial breath sounds  
• Worsening gas exchange (e.g., O2 desaturations (e.g., PaO2/FiO2 <240)7, increased 
oxygen requirements, or increased ventilator demand) 
As the Modified CDC criteria is simpler and most of our lab culture reports are 
qualitative and not quanitative, It is preferred to HELICS criteria and thus used in this 
study. 
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C, Modified CPIS scoring 
Clinical Pulmonary Infection Score is based on multiple variables including 
temperature, WBC count, tracheal secretion, oxygenation, radiography and culture. 
Inclusion of 'culture' in the diagnostic criteria can delay the diagnosis of VAP. 
Modified CPIS scoring system is introduced by excluding the 'culture' from the 
variables considered.  
Table B-  CPIS score calculation (adapted from 'Ventilator-Associated Pneumonia: 
The Clinical Pulmonary Infection Score as a Surrogate for Diagnostics and 
Outcome'-  Marya D. Zilberberg and Andrew F. Shorr)(16) 
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A score of 7 or more in modified CPIS is considered as ' high probability' for 
Ventilator Associated Pneumonia. 
As there is no gold standard for the diagnosis of VAP so far, a combination of 
clinical, radiological and microbiological assessment have to be applied for an early 
detection of VAP. Clinical suspicion of VAP arises if there is a fever of >38.3degree 
celsius, purulent tracheal secretions, leukocytosis> 10,000/mm3 or leukopenia< 
 28 
 
4000/mm3 and the presence of a new radiological opacity in the chest X-ray. But 
there can be many other causes for these clinical presentations apart from VAP. It 
decreases the specificity of the diagnosis of VAP by using clinical criteria alone. 
According to a study conducted by Fagon et al, clinical criteria in diagnosis of VAP 
has false positivity of  20-25% and a false negativity of 30-35% (6). 
 
MICROBIOLOGICAL SPECIMENS 
 
A, Non-quantitative or semi-quantitative  samples :- 
It includes Gram stain and the culture of tracheal aspirate. It has the advantage of that 
there is no need of technical expertise or special equipment or technology, but it is 
reproducible.  But the specificity and sensitivity of these tests to a diagnosis of VAP is 
low. The growth can be a mere colonisation.  In a study were 48 patients having 
respiratory failure are investigated and followed up, the non-quantitative tracheal 
culture and open lung biopsy had a concordance of only 40%  (17).  These cultures are 
more sensitive and specific, when the sample is adequate and there is no change or 
addition of antibiotic in the previous 72 hours. 
Poor positive predictive value of these cultures will result in over diagnosis and over 
treatment of VAP.  Depending more on the clinical signs and symptoms will have an 
opposite effect .  
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B, Quantitative culture samples :- 
Various methods to get good samples include-  
1, Quantitative ET Aspirate   
2, Samples from distal airway through an endobronchial catheter 
3, Blind bronchial sampling 
4, Sampling by a protected telescoping catheter  
5,  Bronchoscopic Broncho-alveolar lavage 
6, Protected BAL (mini-BAL) 
7, Bronchoscopic Protected Specimen Brush 
'Where to sample?' is decided based on the site of the opacities in the radiological 
evaluation. Oropharyngeal colonization in the sample is suggested by  
-  more than 1% epithelial cells 
- 10 or more epithelial cells per low-power  
. 
Threshold values for each and every type of quantitative culture samples has been 
decided and they are expressed as Colony Forming Units per milliliter. If the CFU/ml 
of a particular sample is more than the threshold value for that particular sample, then 
a diagnosis of Ventilator Associated Pneumonia s made.  Threshold values of various 
sampling methods are mentioned below :- 
1, Quantitative culture of ET aspirate - ≥105 to 106  CFU/ml 
2, Bronchoscopic BAL -  ≥104    CFU/ml 
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3,  Bronchoscopic Protected Specimen Brush  ≥103 CFU/ml (18) 
 
 
COMMON ORGANISMS 
 
 
1,  Pseudomonas species 
2, Other highly resistant Gram-negative bacilli 
3, Staphylococci 
4, Enterobacteriaceae 
5, Streptococci 
6, Haemophilus species (19) 
 
Resistant organisms such as Pseudomonas, Acinetobacter species and methicillin-
resistant Staphylococcus aureus (MRSA) are commonly seen after - 
a, Prior antibiotic treatment 
b, Prolonged mechanical ventiation 
 
Atypical bacteria, fungi and viruses can also cause VAP, but such pneumonias are not 
studied in detail.  
The micro-organism that causes the VAP varies depending on 
- The patient profile 
- In which ICU he was admitted 
- Country 
- The day of occurence of VAP (post intubation) (20)  
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Early onset VAP is usually caused by   
- Staphylococcus aureus 
- Strpetococcus pneumonia 
- Haemophilus influenzae 
Late onset VAP is generally caused by  
- Pseudomonas aeruginosa 
- Acinetobacter 
- Enterobacter 
- MRSA (21)  
 
In a study conducted by Varun Goel et al in a medical college in Karnataka showed 
that out of 53 cases they followed up 3.77% were polymicrobial, 49.09% was due to 
Acinetobacter baumannii and 30.9% was due to Pseudomonas aeroginosa, which were 
multi-drug-resistant (22). The background knowledge of the microbiological profile 
and sensitivity pattern of organisms causing VAP helps the physician to initiate the 
appropriate anti-microbial therapy at the earliest. 
Patients with VAP caused by Staphylococcus aureus and Pseudomonas aeroginosa are 
at high risk, due to their resistance to drugs and high mortality(23). Most of the 
resistant organisms occur in late VAP. Pseudomonas are commonly seen in those who 
are on steroids, previously received antibiotics or having structural lung disease.   
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ANTI- MICROBIAL THERAPY 
 
Once the samples for microbiological evaluation was obtained, it is advisable to start 
on an empiric regimen. Delay in initiating the treatment will result in increased 
morbidity and mortality.  In a study were 430 patients who developed VAP was  
followed up, 34% of those who did not receive immediate empiric antimicrobial 
therapy, incidence of shock was 28.8% , whereas those who received was 17.1%  and 
attributable mortality was 24.7% , where as it was 16.2%, in those who received 
appropriate antibiotic therapy (24).  Appropriate and immediate empiric therapy 
should be initiated in patients whom a diagnosis of VAP is suspected. In a study 
where outcomes in patients whom empiric antibiotic therapy was initiated within 24 
hours of the diagnosis was compared to those who received antibiotic therapy after 24 
hours (25).  Rates of bacteremia and mortality were significantly increased in those 
who received delayed treatment.   
The American Thoracic Society recommends aggressive management with empiric 
anti-microbial treatment in late VAPs and in those who are at risk in getting infected 
with drug resistant organisms. The recommended empiric regimen in such patients 
include 
a, Anti-pseudomonal betalactem - betalactamase inhibitor / anti-pseudomonal 
cephalosporins/ anti-pseudomonal carbapenems   plus 
b, Anti-pseudomonal fluoroquinolone or aminoglycoside  plus 
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c, Vancomycin or Linezolid (26). 
 
-A FLOW CHART FOR THE ANTIMICROBIAL THERAPY 
If clinical suspicion of VAP is high with a modified CPIS score of more than 6, 
initiate on empiric therapy after sending ET aspirate for culture and sensitivity.  
                                                                  
Re-assess after  day-3,  if the modified CPIS score is less than 7 and culture did not 
show any growth, discontinue the antibiotic. If the modified CPIS score is equal to or 
more than 7, optimize the antibiotic according to the culture and sensitivity of the 
organism isolated in the ET aspirate culture.  
                                                                       
Re- assess the patient on day-7 for clinical improvement. If there is complete 
resolution of signs and symptoms, stop the antibiotic. If there is no resolution or there 
is worsening of the clinical signs and symptoms, thoughts are 
a,  Non-Fermenting Gram Negative Bacilli requires a longer duration of therapy. 
b, Complicating issues like abscess or empyema should be excluded. 
c, Re-evaluation should be done for secondary infection with a drug resistant 
organism. 
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PREDICTORS OF POOR OUTCOME 
 
 
      The Clinical Pulmonary Infection Score (CPIS) was proposed by Pugin et al. They 
showed that CPIS has a good correlation with bronchial lavage culture bacterial index 
and that it can be as good a diagnostic predictor of VAP, as bronchial lavage 
quantitative culture (27). In a prospective study done in Beijing, it was found that 
there is a significant relation between CPIS score and duration of mechanical 
ventilation (r = 0.526, P = 0.00), duration of ICU stay (r = 0.449, P = 0.00) and the 
duration of total hospital stay (r = 0.519, P = 0.00) (28).  
 
     A high APACHE-II score also was found to be having a significant correlation 
with the diagnosis and outcome of VAP (18). In a retrospective cohort study, 
APACHE II score >27 at onset of VAP  was found to be an independent predictor of 
the mortality ( ROC AUC: 0.841: Sensitivity: 70%; Specificity: 90.6%; p=0.001) (29) 
.  
 
Multi Organ Dysfunction Score was developed by Marshall et al, which includes 
evaluation of failure of 6 organs- Respiratory, hematologic, hepatic, cardiovascular, 
neuronal and renal. Each one is given a score from 0-4 based on extend of damage. 
Study show that , for a total points of 9 to 12 the mortality rate is about 25% and it 
gradually increases with the increase in total points. 75% mortality for a total point of 
17- 20 and 100% for >20 (30). MOD score at diagnosis of VAP and the comparison 
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with the outcome will help us to understand the influence of other organ damage in the 
outcome of VAP patients. 
 
 
          Many biomarkers were considered and studied in association with VAP, as 
early indicators, treatment response markers and outcome predictors. Midregional pro-
atrial natriuretic peptide-  MR proANP, C-terminal provasopressin-copeptin-  CT-
proAVP  and procalcitonin were found to be indicators of sepsis and predictors of 
mortality (31)(32)(33). In a prospective observational study done by Ashraf Abd El 
Halim et al in Egypt, a significant statistical difference (p value < 0.001) was found in 
the serum Procalcitonin levels among VAP patients,  non VAP-ICU patients and 
healthy controls (1.54 ± 0.5 ng/ml , 0.06 ± 0.03 ng/ml and  0.04 ± 0.02 ng/ml 
respectively) (34). In a study done by Charles Edouard et al, they found out that on 
Day 1, serum procalcitonin > 1 ng/ml is the strongest indicator of poor outcome (odds 
ratio of 12.3). On Day 3, a P/F ratio < 210 mm Hg and serum procalcitonin of > 1.5 
ng/ml were more strongly associated with poor outcome. On Day 7, serum 
procalcitonin > 0.5 ng/ml was the strongest independent predictor of poor 
outcome,(odds ratio of 64.2) (9). There are multiple studies which show that rate of 
fall of procalcitonin levels can be used as a prognostic factor to predict the outcome in 
VAP patients. But multiple procalcitonin level estimation is not economically 
practical in our setting as the cost requirement is high. In this study, we'll be trying to 
correlate the initial procalcitonin level at the time of diagnosis of VAP to the 
prediction of outcome. 
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PREVENTION 
 
 
        Prevention is better and easier than cure.  Strategies for preventing VAP are 
described in detail by The Society for Healthcare Epidemiology of America, in their 
2014 update on VAP. Some prevention strategies are :- 
a, Preventing aspiration 
Aspiration is an important risk factor for both hospital and ventilator acquired 
pneumonia. Important modalities for aspiration prevention are- 
1, Positioning of the patient 
Supine position of a ventilated patient predisposes to aspiration. Head end should be 
elevated by 30 to 45° (35).  Supine position will pre-dispose a patient to 
microaspiration of the gastric contents when compared to other positions (36)(37). 
Even if there is no difference in the mortality detected, it is advisable to keep the 
ventilated patient in the semi-recumbent position, if there is no contraindication. 
2, Subglottic drainage  
Subglottic secretion drainage lessen the chance of aspiration and thus the incidence of 
VAP. Modified endo-tracheal tubes are available which will help in continuous or 
intermittent drainage of the subglottic secretions. But cost is of concern.  
A meta-analysis showed that the drainage of the subglottic secretions will reduced the 
length of the ICU stay, days of mechanical ventilation and prolongs the time to the 
 37 
 
onset of VAP. But this strategy also does not show any improvement in the mortality 
(38). 
b, Gastric volume monitoring  
It is a standard practice to monitor the gastric residual volume prior to increase in the 
gastric feed volume. It was thought to be helpful in preventing the accumulation of the 
gastric content leading to vomiting and thus aspiration. But several studies had shown 
that there is no correlation between the gastric volume monitoring and incidence of 
VAP, instead it was noticed that such monitoring will lead to unnecessary reduction in 
the calorie provided to the patient (39). 
c, Decontamination of the digestive tract  
Decontamination of the digestive tract  using antiseptics or non-absorbable antibiotics 
in the oropharynx is done with an intention to decrease the colonization in the upper 
respiratory tract. Poor oral hygiene in ventilated patient, in whom the normal 
mechanical methods of oral hygiene is inhibited will lead to colonization of the dental 
and the gingival plaques by aerobic pathogens. 
In a meta-analysis done in 2007, which included 11 trials, showed that the incidence 
of VAP was reduced significantly in those who received oral application of 
antiseptics/ antibiotics (40).  
d,Probiotics  
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Probiotics are microorganisms from humans that can persist in the lower intestinal 
tract and provide a benefit to the host in terms of health (41).  Various studies had 
shown benefit in preventing VAP, but no advantage in mortality prevention was 
noticed. 
e, Silver-coated endotracheal tube 
NASCENT, a single blinded randomized trial,  in 2003, compared silver coated ETT 
with an uncoated ETT in ventilated patients ventilation (42). This study showed that 
incidence of microbiologically confirmed VAP was lower in those who had Silver 
coated ETT, in comparison with those who normal ETT. A retrospective analysis in 
the same cohort later showed a reduced mortality in the silver coated ETT group. 
 
f, Glucocorticoids  
Use of glucocorticoids was not shown to decrease the incidence of Hospital Acquired 
Pneumonia (HAP) in Traumatic brain injury patients (43), but it had shown benefit in 
reducing HAP in Acute Respiratory Distress Syndrome patients (44). Further studies 
are required to establish the benefit of steroids in ventilated patients. 
g, Others 
1, Glove and gown for the nursing staff 
2, Endotracheal tube cuff pressure >20 cm H20 
3, Orogastric rather than nasogastric feeding tubes 
4, Avoiding nonessential tracheal suctioning 
 39 
 
        
       In 2007, a meta-analysis was done to compare the closed endotracheal suctioning 
with open endotracheal suctioning in preventing Ventilator Associated Pneumonia 
(45) . Nine randomized control trials were included in the same. This analysis showed 
that there is no superiority for closed endotracheal suctioning above open method in 
decreasing the incidence of VAP or ICU mortality.  
        
 
        Mortality rate in VAP ranges between 20% - 76% (46). Other than significant 
mortality, it also causes significant morbidity and indirect expenditure in terms of loss 
of pay , expenses of the bystander and miscellaneous expenses, due to the prolonged 
hospital stay. In a retrospective study the cost of treatment of a VAP was found to be 
five times more than a non-infected patient who was treated in ICU (47). Thus it is 
important to detect VAP and initiate adequate and appropriate therapy as early as 
possible. And it is also important to understand  and explain the outcome of therapy 
and prognosis of the patient based on the clinical scores and biomarkers available. 
 
     Even if multiple studies had happened before on different aspects of VAP, it is 
important to have a significant study analyzing all these data in a single cohort, in a 
teaching institute in South India. In CMC.Vellore Medical ICU, about 300-350 
patients get admitted every year. About 70% of them undergo invasive ventilation. 
From August2013-November2013, 12 patients got VAP. But there was 28 VAPs 
reported in MHDU in the same period.  Focus of  this study is to get detailed 
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information on the clinical profile of VAP, microbiological profile, prognosis 
predictors that can be assessed at the time of diagnosis itself from a single cohort of 
patients ( intubated patients in medical and surgical ICUs and HDUs, and AICU  in 
CMC,Vellore over 12 months of study period). The incidence of VAP also will be 
looked at. 
 
 
 
 
 
                                 
MATERIAL AND METHODS 
 
 
 
 
 
This prospective observational study was conducted in the various 
Intensive Care Units in Christian Medical College, Vellore which is a tertiary referral 
centre in Tamil Nadu. Approval of the Institutional Review Board at Christian 
Medical College was obtained in October 2013 (IRB Min No. 8449).  
STUDY DESIGN 
 
Observational study. 
 
STUDY PERIOD 
 
February 15th  2013 to February 15th 2015. 
 
SETTING 
 
The study was conducted in the Medical, Surgical and A-Block 
Intensive Care Units in Christian Medical College and Hospital, Vellore. 
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PARTICIPANTS 
 
    Among the patients admitted in the Medical, Surgical and A- Block 
Intensive Care Units in Christian Medical College, Vellore, during the study 
period, those who developed Ventilator Associated Pneumonia as per the 
Modified CDC criteria. 
 
 
Inclusion criteria: 
 
 
• Intubated patients admitted in ICU - MICU/MHDU,  SICU/SHDU, AICU 
in Christian Medical College, Vellore 
• Clinico-radiological evidence of pneumonia 
 
 
 
 
Exclusion criteria: 
 
• Pneumonia before intubation or within 48hrs post intubation 
• Intubated outside 
• Any abnormal opacity on chest x ray at the time of intubation 
 
 
SAMPLE SIZE  
 
 
This is a descriptive study where all the intubated patients admitted in 
MICU/MHDU,SICU/SHDU,AICU,KHDU of CMC, Vellore within a period 
of 12 months from the beginning of the study who develops VAP will be 
evaluated and followed up 
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 METHODOLOGY- 
    Patients admitted in Medical, Surgical and Respiratory medicine ICUs and 
HDUs in CMC, Vellore for a period of 12 months will be followed up. Any 
patient with a new onset fever, purulent secretions, leukocytosis, decline in 
oxygenation will be investigated with a Chest X-ray. If a physician diagnosis 
of Hospital Acquired Pneumonia is made, the patient will be included.  The 
diagnosis will be based on the Modified CDC Criteria based on 2014 
guidelines. 
 
CPIS score, MOD Score and APACHE-II score will be calculated, 
Procalcitonin levels and microbiologic results of any respiratory and blood 
sample cultures will be obtained. They will be followed up for the rest of the 
ICU/HDU and hospital stay till the discharge ( or death in hospital). 
 
'Resistant organisms' were defined as per the recommendations by the Centers 
for Disease Control and Prevention (CDC) and the European Centre for 
Disease Prevention and Control (ECDC) , which was published in Clinical 
Microbiology and Infectious disease in 2011. 
 
A difference of 2 ICU days and 4 hospital days are considered as clinically 
significant difference in this study. 
 
 
 43 
 
MAIN OUTCOME MEASURES- 
-Clinico-radiological features will be analyzed 
-The microbiological profile of organisms causing VAP in various ICU/HDUs 
will be analyzed 
-The correlation between CPIS Score, MOD Score,  APACHE-II Score and 
Procalcitonin levels at the diagnosis of VAP and outcome in terms of  number 
of days of ICU/HDU stay, number of days of hospital stay and mortality will 
be analyzed separately. 
 
VARIABLES 
               
 The ICU/HDU where the patient is admitted 
 Microbiological profile of organisms 
 Early and late VAP 
  CPIS score 
 APACHE-II score 
 MOD Score 
 Procalcitonin levels 
 Number of days of ICU/HDU and hospital stay 
 Discharged/died 
 
DATA SOURCES/MEASUREMENT:   
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    All the intubated patients in MICU/MHDU, SICU/SHDU, AICU and KHDU 
for 12months will be considered. The ICU registrars will be well informed 
when to suspect VAP. When VAP is suspected in a patient Chest x-ray will be 
done, and ET-aspirate and Procalcitonin levels will be sent for that patient and 
the principal investigator will be informed about the patient. The patient will be 
seen by the Principal investigator on the same day and the CPIS score, MOD 
Score and APACHE-II score of that patient will be calculated .  
                  The patient will be followed up throughout his stay in the hospital. 
His number of days of ICU/HDU stay , hospital stay and the final outcome 
(discharged/ death) will be noted. 
 
 
STATISTICAL METHODS:  
 
      Logistic regression analysis was done to determine the association between 
the continuous variables -Procalcitonin, Modified CPIS Score, MOD Score and 
APACHE-II Score at the time of diagnosis, and the final outcome in VAP ( 
Death/ discharged). A survival analysis was done to calculate the mean/ median 
survival period in VAP patients ( ICU stay and Hospital stay) and the 
association with the Procalcitonin, Modified CPIS score, MOD Score and 
APACHE-II Score at the time of diagnosis. Ranksum Test was used to compare 
the median values of a variable among 2 groups, and Kruskal Wallis test is 
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used to compare the median values of a variable among the three ICUs. T-Test 
is applied to compare the mean value of a variable among 2 different groups 
and ANOVA test is used to compare the mean values of various variables 
among the different ICUs. 
 
COMPLETE BUDGET PLAN – 
 
    The tests included in this study is usually done in the ICUs as a part of the 
protocol      for the infections.  Therefore extra expenditure was not estimated 
for the study. 
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RESULTS 
 
 
    
 
 
  3005 intubated patients were managed in the Medical, Surgical and A-block ICUs 
during the study period from 15th february 2014 to 15th february 2015.  200 patients 
were evaluated due to the clinical suspicion of Ventilator Associated Pneumonia. Of 
which 78 patients fulfilled the Modified CDC criteria and the Inclusion criteria of the 
study, and they were followed up during the stay in the hospital, till discharge/ death. 
Patients who had any lung opacities at the time of admission were excluded, even if 
they had fulfilled the Modified CDC criteria for the diagnosis of Ventilator Associated 
Pneumonia. It was done so, to avoid any contamination of the data  as the objective 
was to find out the clinical and biological profile of the VAP in our ICUs. 
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DEMOGRAPHIC AND CLINICAL DATA OF THE 
COHORT 
TABLE- 1. A, Demography of the cohort   B, Demography of the AICU arm   C, Demography of the Medical 
ICU arm  D, Demography of the Surgical ICU arm 
A, 
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B, 
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C, 
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D, 
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The mean age of the patients included in the study was 45years.  Mean day of 
development of Ventilator associated pneumonia (VAP) was 7 days post intubation. 
They had an average of 14 days of hospital stay and 23 days of total number of days in 
the hospital.  Only 59 patients had Procalcitonin levels analyzed. One patient was 
discharged at request from the ICU  itself, before completion of the treatment. So he 
was not included in the analysis for the primary objective of  'prognostic factors 
towards the outcome'.  
 
 
Patients from the Surgical ICU had a mean age of 45 years. Mean days to 
development of VAP was 7 days. Average number of ICU stay was 15 days and that 
of total hospital days was 22 days.  Patients from Medical ICU had an average age of  
46 years , mean days to development of VAP was 6 days, ICU stay for 15 days and 
hospital stay for 25 days. AICU patients had an average age of 47 years, mean days to 
development of VAP was 12 days, ICU stay of 9 days and Hospital stay of 15 days. 
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CLINICAL PROFILE 
------------------------------ 
Table 2   Significant features of the Cohort 
 
 
 
 AICU MICU SICU TOTAL P 
VALUE 
Mean 
AGE(yrs) 
47.17 
(22.28) 
45.78 
(18.53) 
44.74 
(16.92) 
45.47 0.95 
Median 
Hosp Days  
8 
(3-47) 
13.5 
(1-103) 
18 
(1-71) 
15 0.43 
Median ICU 
Days  
7.5 
(3-20) 
10 
(1-103) 
11 
(1-58) 
10 0.50 
Median Day 
of 
developing 
VAP  
8 
(4-26) 
5 
(3-28) 
5 
(3-15) 
6 0.16 
Median 
APACHE III  
108* 
(95-
146) 
72.5 
(38-
132) 
71 
(28-
137) 
76 0.009 
MODS 12 
(4-16) 
7 
(3-14) 
8 
(3-16) 
8 0.07 
Mod CPIS 6 
(5-8) 
6 
(3-9) 
5 
(3-7) 
5 0.05 
Procalcitonin 
(ng/dl) 
13.86 
(1.25-
149) 
3.11* 
(0.06-
51,74) 
14.37 
(0.08- 
159.7) 
7.85 0.012 
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Age is represented as mean age and standard deviation is mentioned in closed bracket 
below the mean value. Rest of the variables including Hospital days, ICU days, Day of 
developing VAP, APCHE-III, MODS, Modified CPIS and Procalcitonin levels were 
taken as the median, as there was a wide range of values. The minimum and maximum 
values are mentioned in the closed brackets below the median value. 
 
ANOVA test was used to compare the mean age between the three ICUs and Kruskal 
Wallis test was used to compare the median  of the rest of the variables from the three 
ICUs. 
*-- APACHE-III score was significantly high in the AICU arm, when compared to the 
rest of the cohort.  The median score was 108 in AICU arm, where as average of all 
the median values were 76. (p=0.009). The Procalcitonin level was significantly low 
in the Medical ICU arm- 3.11ng/dl , in comparison to 13.86 ng/dl and 14.87 ng/dl in 
AICU and Surgical ICU respectively (p=0.012). There was no significant difference 
among the 3 different arms in respect to the variables such as age, median APACHE 
III, modified CPIS, MOD score and Procalcitonin levels.  
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EARLY AND LATE VAPS-  PROPORTION 
 
 
Table 3.  Early and Late VAP - Comparison among the 3 ICUs 
 
 EARLY VAP  LATE VAP  
AICU  1/6  (16.67%)  5/6  (83.33%)  
MICU  17/41 (41.46%)  24/41  (58.54%)  
SICU  11/31  (35.48%)  20/31  (64.51%)  
TOTAL  29/78 (37.18%)  49/78  (62.82%)  
   p=0.486 
 
37.18% had early VAPs. Incidence of early VAP (within 4 days of intubation ) was much 
lesser than the incidence of late VAP (after 4 days of intubation ) in all the ICUs.  
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ANOVA test was used to compare the values from the various ICUs. There was no 
significant statistical difference noticed between the three ICU on the incidence of the 
Early and the Late VAP. 
 
SEX DISTRIBUTION 
 
 
Figure 1  Sex distribution of the cohort in the various arms 
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Table 4  Sex distribution of the cohort in the various arms 
 
 
 
SEX AICU MICU SICU TOTAL 
FEMALE  % (n) 16.67 (1) 34.15 (14) 51.61 (16) 39.74 (31) 
MALE      % (n) 83.33 (5) 65.85 (27) 48.39 (15) 60.26 (47) 
 
p=0.158 
 
 
 
ANOVA test was used to compare the sex distribution among the three arms and there 
was no significant difference noticed.  There were 31 females (39.74%) and 47 males 
(60.26%) in the cohort. 
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PATIENTS ADMITTED IN ICU WITH A PRIMIARY 
DIAGNOSIS OF INFECTIOUS ORIGIN 
 
 
 
 
Figure 2   Proportion of patients admitted in ICU primarily with a infectious disease. 
 
 
 
 
 
 
 
25.64% of all VAP patients had primarily infectious diseases as a reason for the ICU 
admission. 
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PROPORTION OF IMMUNOCOMPROMISED  
PATIENTS 
 
 
 
Figure 3  Proportion of the patients in the cohort with a immune compromised status. 
 
 
 
 
 
Majority of the patients under this study were immunocompetent.  11.54% of the 
study population were immunocompromised. Haematological malignancies, 
disseminated malignancies on chemotherapy, liver and renal cell failure were the 
causes of immunosuppression. 
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DAY OF ONSET OF VAP 
 
 
 
Figure 4. Proportion of patients getting VAP, as the intubated days progress. 
 
 
 
 
 
37.18% of the patients developed VAP in the first 4 days.  32.05% developed VAP  
between the  5th and the 7th day of post intubation. 11.54% developed VAP between 8th and  
10th day, 10.26%  between 11th and 13th day, 5.13% between 14th and 16th day,  3.85%  
developed VAP after 16th day of post intubation. 
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Figure 5  Development of VAP as the intubated days progress 
 
 
 
 
 
 
 
37.18% of the cohort developed VAP by day 4 of intubation. It increased to 69.23% by day 7 
and 80.77% by Day 10. 96.15% developed VAP by day 16 of intubation. 
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MORTALITY 
 
Table 5  Mortality in various ICUs 
 
a37.18% 
  
  
  MORTALITY AICU MICU SICU TOTAL 
DEATH (n) 100 (6)* 30 (12) 38.71 
(12) 
38.96 
(30) 
ALIVE (n) 0 70 (28) 61.29 
(19) 
61.04 
(47) 
 
p=.005 
 
 
 
ANOVA test was used to compare the mortality among the patients who had developed VAP 
in various ICUs.  *In AICU the mortality was 100% ( case fatality of VAP ) which was 
significant in comparison with the mortality rates in medical and surgical ICU.  
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Figure 6  Mortality in various ICUs 
 
 
 
 
 
 
 
 
There was an overall mortality of 38.96%. 
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BACTERIOLOGICAL PROFILE 
 
45 of 78 patients (57.69%)  had multiple organisms grown in the ET aspirate culture in 
significant amount. 
 
Table 6.  Common organisms in various ICUs 
 
 
 PSEUDOMONAS  KLEBSIELLA  ACINETOBAC
TER  
AICU  2/8  (25%)  3/8    3/8 (37.5%)  3/8  (37.5%)  
MICU  13/63  (20.63%)  7/63 (11.1%)  30/63  (47.62%)  
SICU  8/43  (18.6%)  6/43  (13.95%)  18/43  
(41.86%)  
TOTAL  22/121  (18.18%)  15/121  
(12.39%)  
49/121  (40.5%)  
 
 64 
 
The bacteriological profile was almost the same in all the ICU , irrespective of 
the cases being surgical or medical. Ainetobacter sp was the most commom 
organism, followed by pseudomonas and the klebsiella.  There was no 
difference noticed in the bacteriological profile , between the early and late 
VAP.  
Other organisms which were detected in this cohort were-  
• Serratia  
• Staphylococcus aureus  
• E.coli  
• Proteus sp 
• Sterotrophomonas  
• NFGNB 
• Enterobacter  
• Providencia  
• Citrobacter  
• Chrysobacterium indolgeis  
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Figure 7. Common organisms in various ICUs 
 
 
 
 
 
 
 
 
PROPORTION OF RESISTANT ORGANISMS 
 
 
Resistant organisms- 
 
• AICU- 5/6  (83.33%) 
 
• MICU- 37/41  (90.24%) 
 
• SICU- 29/31  (93.55%) 
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• TOTAL- 71/78 (91.03%)  
 
 
 
Figure 8  Proportion of resistant organisms in various ICUs 
 
 
 
 
 
 
p=0.702 
 
 
 
 
Proportion of resistant organisms grown in the ET Aspirate from the cohort was 
91.03%. ANOVA test was used to compare the proportion of resistant organisms in 
various ICUs and there was no statistically significant difference noticed. 
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OUTCOME 
---------------- 
 
 
 
MORTALITY, ICU AND HOSPITAL STAY 
 
 
Table 7.   Mortality Predictors 
 
 
 
 
Age is represented as mean age and standard deviation is mentioned in closed bracket 
below the mean value. Rest of the variables including APCHE-III, MODS, Modified 
CPIS and Procalcitonin levels were taken as the median, as there was a wide range of 
values. The minimum and maximum values are mentioned in the closed brackets 
below the median value. 
 MORTALITY ALIVE p- VALUE 
Procalcitonin 
(ng/dl) 
10.54 
(0.31-157) 
6.36 
(0.06-159.7) 
0.15 
APACHE III 96.00 
(52-146) 
66.00 
(28-132) 
<0.001 
Mod CPIS 5.50 
(3-9) 
5.00 
(3-9) 
0.44 
MODS 10.00 
(4-16) 
7.00 
(3-14) 
0.004 
AGE (yrs) 47.00 
(19.08) 
45.00 
(17.56) 
0.57 
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Ranksum Test was used to compare the median values of different scores and 
procalcitonin levels, and T-test was used to compare the mean 'age' among those who 
succumbed to their illness and those who survived. Median  APACHE-III score 
among those who died was 96, where as the score among those who survived was 66. 
Median MOD score among those who died was 10 and the score among the survivors 
was 7. The difference in both APACHE-III score and the MOD score between the two 
groups were statistically significant. There was no significant difference noticed in 
relation to modified CPIS score and the Procalcitonin levels. 
 
 
PROCALCITONIN 
 
 
Table 8. Mean procalcitonin in the survivors and those who died. 
 
 
 
 
 MEAN 95% CI 
MORTALITY  (n=24) 35.36 14.14 - 56.57 
ALIVE   (n=35) 17.47 6.42 - 28.52 
 
 
p= 0.1007                       
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Mean Procalcitonin level among those who survived was 17.47 and those who 
succumbed to their illness was 35.36. But there was no statistical significance noticed. 
 
Table 9. Procalcitonin level of 4ng/dl as a predictor of mortality 
 
Procalcitonin (ng/dl) Mortality Alive Total 
<4 (%) 8 (33.33) 17 (48.57) 25 (42.37) 
>4 (%) 16 (66.67) 18 (51.43) 34 (57.63) 
Total 24 35 59 
 
p= 0.245 
 
 
 
 
A procalcitonin level of 4 ng/dl was taken to see whether a high level like that can be 
considered as a predictor of mortality. But there was no significance noticed. 
Procalcitonin failed to stand as an independent predictor of mortality. 
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Figure 9  Median survival analysis -Procalcitonin 
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The median survival for patients with Procalcitonin <4 ng/dl was 37 ICU days, 
whereas those who had Procalcitonin level  more than or equal to 4 ng/dl had only 16 
ICU days (p=.06). But the difference fell short of statistical significance. 
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ICU AND HOPSITAL DAYS 
 
Table 10. Correlation of Procalcitonin and ICU days 
 
PROCALCITONIN Median ICU days Min-Max 
< 4ng/dl 13 1 - 103 
>/=4ng/dl 9.5 1 - 58 
 
p=0.261 
 
Patients with a procalcitonin level of less than 4ng/dl at the time of diagnosis had a 
median of 13 ICU days and those with a procalcitonin level equal to or more than 
4ng/dl had 9.5 days, the difference was not statistically significant. 
 
Table 11. Correlation of Procalcitonin and Hospital days 
 
Procalcitonin Median Hospital days Min - Max 
<4ng/dl 26 5 - 103 
>/=4ng/dl 17 7 - 71 
 
p= 0.181 
Patients with a procalcitonin level of less than 4ng/dl at the time of diagnosis had a 
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median of 26 hospital days and those with a procalcitonin level equal to or more than 
4ng/dl had 17 days, the difference was not statistically significant. 
 
APACHE-III 
 
 
 
Table 12  Mean APACHE -III score among the survivors and those who died 
 
 
 
 
 
 MEAN 95% CI 
MORTALITY   (n=30) 94.07 84.33 - 103.81 
ALIVE       (n=47) 69.40 63.11 - 75.7 
 
 
 
    p< 0.001           
 
 
 
Mean APACHE III score of those who survived was 69.40 and those who succumbed to 
illness was 94.07  and it was statistically significant. 
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Table 13  APACHE -III Score of 80 as a predictor of mortality 
 
 
 
APACHE III MORTALITY ALIVE TOTAL 
<80 (%) 11 (36.67%) 33 (70.21%) 44 (57.14%) 
>/=80 (%) 19 (63.33%) 14 (29.79%) 33 (42.86%) 
TOTAL 30 47 77 
 
 
P= 0.004 
 
 
APACHE-III score of 80 or more has a 63.33% sensitivity and 70.21% specificity in 
predicting mortality in  patients with ventilator associated pneumonia. 
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Figure 10  Median survival analysis- APACHE -III 
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The median survival for patients with APACHE-III score <80 was 37 ICU days, 
whereas those who had APACHE-III score  more than or equal to 80 had only 12 ICU 
days (p=.0038). The difference was both clinically and statistically significant. 
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ICU AND HOPSITAL DAYS 
 
Table 14.  Correlation of APACHE III and ICU days 
 
 
APACHE III Median ICU days Min-Max 
< 80 9 1 - 103 
>/=80 14.5 4  - 53 
 
p=0.196 
 
 
Patients with a APACHE III score of less than 80 at the time of diagnosis had a 
median of 9 hospital days and those with a APACHE III score equal to or more than 
80 had 14.5 days, the difference was not statistically, but clinically significant. 
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Table 15. Correlation of APACHE III and hospital days 
 
APACHE-111 Median Hospital days Min - Max 
<80 19 4 - 103 
>/=80 28.50 10 - 67 
 
p= 0.55 
 
 
Patients with a APACHE III score of less than 80 at the time of diagnosis had a 
median of 19 hospital days and those with a APACHE III score equal to or more than 
80 had 28.5 days, the difference did not reach statistical significance, but could be 
clinically significant. 
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Mod. CPIS 
 
 
Table 16. Mean Modified CPIS score among the survivors and those who died 
 
 
 MEAN 95% CI  
MORTALITY  (n=30) 5.5 4.98 - 6.02 
ALIVE   (n=47) 5.26 4.85 - 5.66 
 
 
   
  p = 0.4529         
 
 
The mean mod CPIS score was 5.5 in the patients who succumbed to their illness and 5.26 
among those who survived. There was no significant difference among the both groups. 
 
Table 17. Modified CPIS score of 6 or more as a predictor of mortality 
 
Mod CPIS MORTALITY ALIVE TOTAL 
<6 (%) 15 (50%) 27 (57.45%) 42 (54.55%) 
>/=6 (%) 15 (50%) 20 (42.55%) 35 (45.45%) 
TOTAL 30 47 77 
p= 0.522 
 
Analysis was done to see whether a modified CPIS score of 6 or more can be used as a 
predictor of mortality. But there was no significant correlation noticed. 
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Figure 11  Median survival analysis- Modified CPIS Score 
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The median survival for patients with modified CPIS score <6 was 37 ICU days, 
whereas those who had modified CPIS score  more than or equal to 6 had only 23 ICU 
days (p=.4182).  The difference was clinically significant. 
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ICU AND HOPSITAL DAYS 
 
Table 18. Correlation between  Modified CPIS score and ICU days 
 
Mod.CPIS Median ICU days Min-Max 
< 6 10 1 - 103 
>/=6 10.5 1 - 53 
 
p=0.9313 
Patients with a mod.CPIS score of less than 6 at the time of diagnosis had a median of 
10 ICU days and those with a mod.CPIS score equal to or more than 6 had 10.5 days, 
the difference was not statistically or clinically significant. 
Table 19, Correlation between Modified CPIS score and Hospital days 
Mod.CPIS Median Hospital days Min - Max 
<6 19 4 - 103 
>/=6 22 4 - 67 
 
p= 0.6824 
Patients with a mod. CPIS score of less than 6 at the time of diagnosis had a median of 
19 hospital days and those with a mod.CPIS score equal to or more than 6 had 22 
days, the difference was not statistically significant, but it could be clinically 
significant. 
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MOD SCORE 
Table 20.   Mean MOD score among the survivors and those who died 
 
 
 MEAN 95% CI 
MORTALITY   (n=30) 9.63 8.16 - 11.10 
ALIVE      (n=47) 7.04 6.26 - 7.83 
 
p = 0.0010       
 
The mean MOD Score among those who survived was 7.0 and among those who 
succumbed to illness was 9.6, and it was statistically significant. 
 
Table 21.  MOD score as a predictor of mortality 
 
MODS MORTALITY ALIVE TOTAL 
1-4 (%) 4 (13.33%) 10 (21.28%) 14 (18.18%) 
5-8 (%) 8 (26.67%) 24 (51.06%) 32 (41.56%) 
9-12 (%)* 10 (33.33%) 12 (25.53%) 22 (28.57%) 
>/=13 (%)  8 (26.67%) 1 (2.13%) 9 (11.69%) 
TOTAL 30 47 77 
P=.004 
 
*33.33% of the patients who died had a MOD score between 9 and 12. Specificity of a MOD 
score between 9 and 12 in predicting mortality was 74.47%. This finding was statistically 
significant as well. 
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Figure 12. Median survival analysis- MOD score 
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The median survival for patients with MOD score <9 was 37 ICU days, whereas those who 
had MOD score  more than or equal to 9 had only 14 ICU days (p=.019). The difference was 
both clinically and statistically significant. 
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ICU AND HOSPITAL DAYS 
 
 
 
 
 
Table 22. Correlation between MODS sore and ICU days 
 
 
 
 
MODS MEDIAN ICU DAYS MIN - MAX 
1-4  9 1 - 103 
5-8  11 1 - 34 
9-12  11 3 - 58 
>/=13   7 7 - 7 
 
 
p= 0.8112 
 
 
 
There was no significant correlation noticed between the MODS score at the time of 
diagnosis of VAP and the median days of ICU stay. 
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Table 23. Correlation between MODS score and hospital days 
 
MODS MEDIAN HOSPITAL 
DAYS 
MIN - MAX 
1-4  18.5 5 - 103 
5-8  24 4 - 103 
9-12  24.5 11 - 71 
>/=13   11 11 - 11 
 
 
p= 0.5949 
 
 
There was no significant correlation noticed between the MODS score at the time of 
diagnosis of VAP and the median days of hospital stay. 
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AGE 
 
 
 
Table 24.  Mean age among the survivors and those who died. 
 MEAN 95% CI 
MORTALITY  (n=30) 46.9 39.77 - 54.03 
ALIVE    (n=47) 44.51 39.36 - 49.67 
 
 
 
p= 0.5751           
 
 
 
T-Test analysis was done to compare the mean age among the survivors and those 
who died. 
There was significant association noticed between the 'age' and the outcome, in terms 
of 'mortality'. 
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Figure 13. Median survival analysis- Age 
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The median survival for patients with age less than or equal to 45 years was 23 ICU days, 
whereas those who had age more than 45 years, it was 20 ICU days (p=.75). The difference 
was not significant. 
 86 
 
 
 
 
RESISTANT ORGANISMS 
 
 
 
Table 25  Resistant organism and the mortality 
 
 
 
 MORTALITY ALIVE TOTAL 
SENSTIVE ORG % (n) 10 (3) 8.51 (4) 9.09 (7) 
RESISTANT ORG % (n) 90 (27) 91.49 (43) 90.91 (70) 
 
 
          p=0.825 
 
 
Of those who expired, 10% had sensitive organism grown in the ET aspirate culture 
and 90% had resistant organism. Mortality rate among those who had sensitive 
organism was 42.9%, whereas among those who had resistant organism was 38.6%. 
But these values were not statistically significant. The difference could be due to the 
fact that the commonest organism found in the study- Acinetobacter is a resistant 
organism, but responds well to the appropriate  therapy. 
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Figure 14  Resistant organism and mortality 
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POLYMICROBIALS 
 
 
Table 26.  Poly-microbials and mortality 
 
 
 MORTALITY ALIVE TOTAL 
SINGLE ORGANISM 
(%) 
17 (56.67%) 27 (57.45%) 44 (57.14%) 
POLY MICROBIAL 
(%) 
13 (43.33%) 20 (42.55%) 33 (42.86%) 
TOTAL 30 47 77 
 
p= 0.946 
 
 
 
56.67% of the patients who succumbed to their illness had single organism grown in 
the ET aspirate culture, where as 43.33% had multiple organisms grown. The 
difference was not statistically significant. Mortality rate in the 'single organism' group 
and the 'polymicrobial' group were 38% and 39% respectively. 
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Table. 27  Poly-microbials and ICU Stay 
 
 
 Median days of ICU stay Min- Max 
Single organism 10 1- 103 
Multiple organism 10.5 1- 30 
 
p= 0.5393 
 
Irrespective of the fact that whether a single organism or multiple organisms were grown in 
the ET aspirate, the median number of ICU days was about 10. 
 
Table 28. Poly-microbials and hospital days 
 
 MEDIAN HOSPITAL DAYS MIN - MAX 
SINGLE ORGANISM 18 4 - 103 
MULTIPLE ORGANISMS 21 5 - 101 
 
p=0.6983 
The median number of hospital days in those who had a single organism grown in 
their ET aspirate was 18 days, whereas those who had multiple organisms grown in 
their ET aspirate had a median number of hospital days of 21, and the difference  was 
not clinically or statistically significant. 
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Figure 15. Median survival- Polymicrobials 
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The patients whose ET aspirate grew only a single organism, had a median survival 
period of 26 ICU days, whereas the patients whose ET aspirate grew multiple 
organisms, the median survival period was 19 ICU days. The difference was clinically 
significant, but it was not statistically significant (p= 0.6812). 
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ACINETOBACTER sp 
 
Table 29. Mortality in patients who had Acinetobacter infection 
 
 MORTALITY ALIVE TOTAL 
ACINETOBACTER 
(%) 
9 (52.94%) 19 (70.37%) 28 (63.64%) 
OTHER ORG (%) 8 (47.06%) 8 (29.63%) 16 (36.36%) 
TOTAL 17 27 44 
 
p=0.242 
 
There was no significant difference in the mortality between those who had grown 
acinetobacter sp in the ET aspirate and those who had grown some other organism ( 
52.94% and 47.06%  respectively). 
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Figure 16. Median survival time in patients infected with Acinetobacter when compared to 
others 
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p-0.81      (3- acinetobacter) 
 
The median survival time of those who had acinetobacter infection was 23 ICU days, 
where as those who had other organism in their ET aspirate was 26 days. The 
difference was not  statistically significant, but it was clinically significant. 
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ICU AND HOSPITAL DAYS 
 
Table 30. Median ICU days in acinetobacter infection and others 
 MEDIAN ICU DAYS MIN- MAX 
ACINETOBACTER 10 1 - 53 
OTHER ORGANISMS 23.5 4 - 103 
 
P= 0.0627 
 
The median number of ICU days those who had grown acinetobacter sp in the ET 
aspirate was 10 days , where as in others it was 23.5 days. The difference was not 
statistically significant. But the difference was clinically significant. 
 
Table 31. Median hospital days in acinetobacter infection and others 
 MEDIAN HOSPITAL 
DAYS 
MIN- MAX 
ACINETOBACTER 14 4 - 67 
OTHER ORGANISMS 39 10 - 103 
 
P= 0.0629 
The median number of hospital days those who had grown acinetobacter sp in the ET 
aspirate was 14 days , where as in others it was 39 days. The difference was not 
statistically significant. But the difference was clinically significant. 
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EARLY AND  LATE VAP 
 
 
 
 
 
Table 32. Mortality in Early and Late VAPs 
 
 
 
     
 DEATH ALIVE TOTAL 
EARLY VAP % (n) 20 (6) 46.81 (22) 36.36 (28) 
LATE VAP % (n) 80 (24) 53.19 (25) 63.64 (49) 
 
 
          p= 0.017 
 
 
 
Among those who died 20% had early VAP and 80% had late VAP. Early VAP had a 
mortality rate of 21.4%, where as Late VAP had a mortality rate of 48.98%. Both were 
statistically significant. Mortality rate in the Early VAP and the Late VAP were 21.4% 
and 48.9% respectively and the significance was statistically significant. 
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Figure 17. Mortality in early and late VAP 
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ICU STAY 
 
Table 33. Median ICU days in Early and Late VAPs 
 
                                         
 MEDIAN ICU 
STAY 
(days) 
EARLY VAP  (n=28) 9.00 
LATE VAP  (n=49) 11.00 
 
 
 
Median of number of ICU stay in the early VAP group was 9 days and that in Late 
VAP group was 11 days. A difference of 2 or more days was considered as a clinically 
significant difference. 
 
Table 34. Median Hospital days in Early and Late VAPs 
 
 MEDIAN HOSPITAL 
STAY(days) 
EARLY VAP (n=28) 17.00 
LATE VAP (n=49) 14.00 
 
 
 
The median number of hospital days among those who had Early VAP was 17 days 
and that with Late VAP was 14 days. As a difference of 4 hospital days was 
considered as clinically significant value, early and late VAP did not show any 
clinically significant difference in this aspect. 
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DISCUSSION 
 
 
 
 
 
Patients who were admitted and intubated in various ICUs during the study period 
were evaluated once they developed signs and symptoms of Ventilator Associated 
Pneumonia. Modified CDC criteria was applied to make a diagnosis of VAP. Patients 
who had lung opacities at the time of admission or intubation were excluded, to ensure 
that only those who with definite VAP were included in this study. This may have 
resulted in the under-estimation of the VAP cases. APACHE-III score, MODS score, 
Modified CPIS score were calculated and the Procalcitonin level was noted at the time 
of  diagnosis of VAP.  The study population was followed up till the day of discharge 
or death.  Clinical profile and bacteriological profile of the study population was 
studied and analyzed in detail. Analysis was done to find out whether various 
previously validated scores and the procalcitonin levels can be used as predictors of 
the clinical outcome- Mortality and in patients who survived, the days of ICU stay and 
the days of hospital stay. A difference of 2 ICU days and 4 hospital days was 
arbitrarily considered as clinically significant difference. 
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The mean age of the patients included in the study was 45years.  Mean day of 
development of Ventilator associated pneumonia (VAP) was 7 days post intubation. 
They had an average of 14 days of hospital stay and 23 days of total number of days in 
the hospital.  Only 59 patients had Procalcitonin levels analyzed. One patient was 
discharged against the medical advice from the ICU  itself, before completion of the 
treatment. So he was not included in the analysis for the primary objective of  
'prognostic factors towards the outcome'.  
 
 
Patients from the Surgical ICU had a mean age of 45 years. Mean day of development 
of VAP was 7 days. Average number of ICU stay was 15 days and that of total 
hospital days was 22 days.  Patients from Medical ICU had an average age of  46 
years , mean day of development of VAP was 6 days, ICU stay for 15 days and 
hospital stay for 25 days. AICU patients had an average age of 47 years, mean day of 
development of VAP was 12 days, ICU stay of 9 days and Hospital stay of 15 days. 
 
Variables including Hospital days, ICU days, Day of developing VAP, APCHE-III, 
MODS, Modified CPIS and Procalcitonin levels were taken as the median, as there 
was a wide range of values.  ANOVA test was used to compare the mean age between 
the three ICUs and Kruskal Wallis test was used to compare the median  of the rest of 
the variables from the three ICUs. APACHE-III score was significantly high in the 
AICU arm, when compared to the rest of the cohort.  The median score was 108 in 
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AICU arm, where as average of all the median values were 76. (p=0.009). The 
Procalcitonin level was significantly low in the Medical ICU arm- 3.11ng/dl , in 
comparison to 13.86 ng/dl and 14.87 ng/dl in AICU and Surgical ICU respectively 
(p=0.012). There was no significant difference among the 3 different arms with regard 
to the other variables.  
 
A total of 37.18% had early VAPs. Incidence of early VAP (within 4 days of intubation ) 
was much lesser than the incidence of late VAP (after 4 days of intubation ) in all the 
ICUs.  ANOVA test was used to compare the values from the various ICUs. There was 
no significant statistical difference noticed between the three ICU on the incidence of the 
Early and the Late VAP. ANOVA test was used to compare the sex distribution among 
the three arms and there was no significant difference noticed.  There were 31 females 
(39.74%) and 47 males (60.26%) in the cohort. 
 
 
25.64% of all VAP patients had primarily infectious diseases as a reason for the ICU 
admission. It includes necrotizing fascitis, meningitis, scrub typhus, sepsis, splenic 
abscess rupture, septic shock, disseminated tuberculosis etc.  Majority of the patients 
under this study were immunocompetent.  A total of 11.54% of the study population 
were immunocompromised. Haematological malignancies, disseminated malignancies 
on chemotherapy, liver and renal cell failure were the causes of immunosuppression. 
 
A total of 37.18% of the patients developed VAP in the first 4 days.  32.05% 
developed VAP  between the  5th and the 7th day of post intubation. 11.54% 
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developed VAP between 8th and 10th day, 10.26%  between 11th and 13th day, 
5.13% between 14th and 16th day,  3.85%  developed VAP after 16th day of post 
intubation. 37.18% of the cohort developed VAP by day 4 of intubation. It increased 
to 69.23% by day 7 and 80.77% by Day 10. 96.15% developed VAP by day 16 of 
intubation. 
 
ANOVA test was used to compare the mortality among the patients who had 
developed VAP in various ICUs.  In AICU the mortality was 100% ( case fatality of 
VAP ) which was significant in comparison with the mortality rates in medical and 
surgical ICU.  All the 6 patients from AICU was critically ill with multiple organ 
dysfunction and many of them were having disseminated or hematological 
malignancies and on chemotherapy. The high APACHE III score for these patients in 
AICU compared to other ICUs throws light to this high mortality rate. There was an 
overall mortality of 38.96%. 
 
45 of 78 patients (57.69%)  had multiple organisms grown in the ET aspirate culture 
in significant amount. The bacteriological profile was almost the same in all the ICU , 
irrespective of the cases being surgical or medical. Ainetobacter sp was the most 
commom organism, followed by pseudomonas and the klebsiella.  There was no 
difference noticed in the bacteriological profile , between the early and late VAP.  
Other organisms which were detected in this cohort were-  
• Serratia  
• Staphylococcus aureus  
• E.coli  
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• Proteus sp 
• Sterotrophomonas  
• NFGNB 
• Enterobacter  
• Providencia  
• Citrobacter  
• Chrysobacterium indolgeis  
 
 5/6  (83.33%) patients from AICU, 37/41  (90.24%) patients from MICU and 29/31  
(93.55%) patients from SICU had significant growth of a resistant organism in there 
ET aspirate culture. A total of 91.03% of the study population had resistant organisms 
in the ET aspirate culture.  'Resistant organisms' were defined as per the 
recommendations by the Centers for Disease Control and Prevention (CDC) and the 
European Centre for Disease Prevention and Control (ECDC) , which was published 
in Clinical Microbiology and Infectious disease in 2011 (48). According to this 
recommendation, an organism which is resistant to drugs from 3 or more different 
group of drugs, to which that particular species is naturally susceptible to, is defined 
as a resistant organism. Proportion of resistant organisms grown in the ET Aspirate 
from the cohort was 91.03%. ANOVA test was used to compare the proportion of 
resistant organisms in various ICUs and there was no statistically significant 
difference noticed. 
 
Mean age and median of various score including APCHE-III, MODS and Modified 
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CPIS and Procalcitonin levels were calculate and analysis was done to find out 
whether they can be used as predictors of the clinical outcome- Mortality and in 
patients who survived, the days of ICU stay and the days of hospital stay. Median 
value of the scores and the procalcitonin levels were used as there was a wide range of 
values. Ranksum Test was used to compare the median values of different scores and 
procalcitonin levels, and T-test was used to compare the mean 'age' among those who 
succumbed to their illness and those who survived. Median  APACHE-III score 
among those who died was 96, where as the score among those who survived was 66. 
Median MOD score among those who died was 10 and the score among the survivors 
was 7. The difference in both APACHE-III score and the MOD score between the two 
groups were statistically significant. There was no significant difference noticed in 
relation to modified CPIS score and the Procalcitonin levels.  
 
Mean Procalcitonin level among those who survived was 17.47 and those who 
succumbed to their illness was 35.36. But there was no statistical significance noticed. 
A procalcitonin level of 4 ng/dl was taken to see whether a high level like that can be 
considered as a predictor of mortality. But there was no significance noticed. 
Procalcitonin failed as an independent predictor of mortality.  As a definite ROC curve 
was not able to be obtained, an arbitrary cutoff of 4ng/dl , which was much higher 
than the cutoff of 1.5ng/dl in the previous studies (9) was used to look for any 
significance in the median survival analysis , as well as the days of ICU and Hospital 
stay. The median survival for patients with Procalcitonin <4 ng/dl was 37 ICU days, 
whereas those who had Procalcitonin level  more than or equal to 4 ng/dl had only 16 
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ICU days (p=.06). But the difference was clinically significant. 
 
Patients with a procalcitonin level of less than 4ng/dl at the time of diagnosis had a 
median of 13 ICU days and those with a procalcitonin level equal to or more than 
4ng/dl had 9.5 days, the difference was not statistically significant. Patients with a 
procalcitonin level of less than 4ng/dl at the time of diagnosis had a median of 26 
hospital days and those with a procalcitonin level equal to or more than 4ng/dl had 17 
days, the difference was not statistically significant.  Apart from the median survival 
in terms of ICU days, our study failed to establish Procalcitonin as a predictor of the 
outcome in VAP patients. May be a continuous monitoring of Procalcitonin and the 
trend of rise or fall in the values, would have been a actual predictor of the outcome. 
 
Mean APACHE III score of those who survived was 69.40 and those who succumbed 
to illness was 94.07  and it was statistically significant. In a previous study comparing 
APACHE III score to King's college hospital criteria, MELD score and APACHE II 
score , as a better predictor of poor outcome or mortality in patients who undergo liver 
transplantation for acute hepatic failure, a APACHE III score of 80 was taken as a 
cutoff (49). This study had shown that APACHE score of 80 or more has a specificity 
of 90% and positive predictive value of 50% in predicting poor outcome. In our study, 
APACHE-III score of 80 or more has a 63.33% sensitivity and 70.21% specificity in 
predicting mortality in  patients with ventilator associated pneumonia. 
 
The median survival for patients with APACHE-III score <80 was 37 ICU days, 
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whereas those who had APACHE-III score  more than or equal to 80 had only 12 ICU 
days (p=.0038). The difference was both clinically and statistically significant. 
Patients with a APACHE III score of less than 80 at the time of diagnosis had a 
median of 9 hospital days and those with a APACHE III score equal to or more than 
80 had 14.5 days, the difference was not statistically, but clinically significant. 
Patients with a APACHE III score of less than 80 at the time of diagnosis had a 
median of 19 hospital days and those with a APACHE III score equal to or more than 
80 had 28.5 days, the difference was not statistically, but clinically significant. In this 
study, APACHE III score, especially a score of more than or equal to 80  was proven 
to be a good outcome predictor in Ventilator Associated Pneumonia.  
 
  
     The mean mod CPIS score was 5.5 in the patients who succumbed to their illness 
and 5.26 among those who survived. There was no significant difference among the 
both groups. Analysis was done to see whether a modified CPIS score of 6 or more 
can be used as a predictor of mortality. Previous studies has shown CPIS score less 
than 6 as an indication to stop antibiotics in patients with ventilator associated 
pneumonia. But there was no significant correlation noticed. The median survival for 
patients with modified CPIS score <6 was 37 ICU days, whereas those who had 
modified CPIS score  more than or equal to 6 had only 23 ICU days (p=.4182).  The 
difference was clinically significant. Patients with a mod.CPIS score of less than 6 at 
the time of diagnosis had a median of 10 ICU days and those with a mod.CPIS score 
equal to or more than 6 had 10.5 days, the difference was not statistically or clinically 
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significant. 
 
     Patients with a mod. CPIS score of less than 6 at the time of diagnosis had a 
median of 19 hospital days and those with a mod.CPIS score equal to or more than 6 
had 22 days, the difference was not statistically significant, but it was clinically 
significant. Modified CPIS score of 6 or more was proven to be a good predictor of 
outcome in VAP, in terms of median survival expressed as ICU days and total days of 
hospital stay, once shifted out from ICU. 
 
    The mean MOD Score among those who survived was 7.0 and among those who 
succumbed to illness was 9.6, and it was statistically significant. 33.33% of the 
patients who died had a MOD score between 9 and 12. Specificity of a MOD score 
between 9 and 12 in predicting mortality was 74.47%. This finding was statistically 
significant as well. The median survival for patients with MOD score <9 was 37 ICU 
days, whereas those who had MOD score  more than or equal to 9 had only 14 ICU 
days (p=.019). The difference was both clinically and statistically significant. There 
was no significant correlation noticed between the MODS score at the time of 
diagnosis of VAP and the median days of ICU stay. There was no significant 
correlation noticed between the MODS score at the time of diagnosis of VAP and the 
median days of hospital stay. 
  
       APACHE III score and MOD Score were proven to be good predictors of 
outcome in VAP patients in terms of mortality, median ICU days of survival and 
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median days of hospital or ICU stay, whereas modified CPIS score and procalcitonin 
levels failed to be so. It might be because of the fact that APACHE III scoring and 
MOD scoring were introduced as predictors of mortality, where as modified CPIS 
score was introduced as a diagnostic criteria. 
 
Other factors like age above 45 years, drug resistant organism grown in the ET 
aspirate culture , significant growth of multiple organisms in the ET aspirate culture 
and late VAP were analyzed to find whether they could be predictors of poor outcome. 
T-Test analysis was done to compare the mean age among the survivors and those 
who died. There was significant association noticed between the 'age' and the 
outcome, in terms of 'mortality'. The median survival for patients with age less than or 
equal to 45 years was 23 ICU days, whereas those who had age more than 45 years, it 
was 20 ICU days (p=.75). The difference was not significant. 
 
     Of all the mortality, 10% had sensitive organism grown in the ET aspirate culture 
and 90% had resistant organism. Mortality rate among those who had sensitive 
organism was 42.9%, whereas among those who had resistant organism was 38.6%. 
But these values were not statistically significant. 56.67% of the patients who 
succumbed to their illness had single organism grown in the ET aspirate culture, 
where as 43.33% had multiple organisms grown. The difference was not statistically 
significant. Irrespective of the fact that whether a single organism or multiple 
organisms were grown in the ET aspirate, the median number of ICU days was about 
10. 
 
 107 
 
    The median number of hospital days in those who had a single organism grown in 
their ET aspirate was 18 days, whereas those who had multiple organisms grown in 
their ET aspirate had a median number of hospital days of 21, and the difference  was 
not clinically or statistically significant. The patients whose ET aspirate grew only a 
single organism, had a median survival period of 26 ICU days, whereas the patients 
whose ET aspirate grew multiple organisms, the median survival period was 19 ICU 
days. The difference was clinically significant, but it was not statistically significant 
(p= 0.6812). 
  
   Acinetobacter was the most common organism grown in the ET aspirate culture 
from the patients with VAP, in our study .  Most of them were resistant to all the drugs 
tested for susceptibility , except Colistin. There was no significant difference in the 
mortality between those who had grown acinetobacter sp in the ET aspirate and those 
who had grown some other organism ( 52.94% and 47.06%  respectively). The median 
survival time of those who had acinetobacter infection was 23 ICU days, where as 
those who had other organism in their ET aspirate was 26 days. The difference was 
not  statistically significant. But the difference was clinically significant. 
 
   The median number of ICU days those who had grown acinetobacter sp in the ET 
aspirate was 10 days , where as in others it was 23.5 days. The difference was not 
statistically significant. But this difference was also clinically significant. The median 
number of hospital days those who had grown acinetobacter sp in the ET aspirate was 
14 days , where as in others it was 39 days. The difference was not statistically 
 108 
 
significant. But the difference was clinically significant. Even if most of the 
Acinetobacter sp grown in the ET aspirate culture was resistant to most of the drugs 
tested for susceptibility, except Colistin, the outcome was good for those who had 
acinetobacter infection when compared to those who had VAP due to any other 
organism. This might be due to the difference in the in-vivo and in-vitro susceptibility 
of this organism to the drugs tested. 
 
Among those who died 20% had early VAP and 80% had late VAP. Early VAP had a 
mortality rate of 21.4%, where as Late VAP had a mortality rate of 48.98%. Both were 
statistically significant. Median of number of ICU stay in the early VAP group was 9 
days and that in Late VAP group was 11 days. A difference of 2 or more days was 
considered as a clinically significant difference. The median number of hospital days 
among those who had Early VAP was 17 days and that with Late VAP was 14 days. 
As a difference of 4 hospital days was considered as clinically significant value, early 
and late VAP did not show any clinically significant difference in this aspect. 
 
Compared to previous studies, this study showed no significant difference among the 
infections caused by the sensitive organism and the resistant organisms, in terms of 
the outcome. APACHE III and MOD score were proved to be good prognostic factors, 
where as modified CPIS score which was developed as a diagnostic scoring system 
failed as a prognostic scoring system, even if the previous studies had showed its 
significance as a prognostic factor. Commonest organism was acinetobacter, not 
pseudomonas. Other factors like age, polymicrobial infection, immunosuppression etc 
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were considered in this study.
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CONCLUSION 
 
 
In Ventilated patients who had a normal chest xray at the time of intubation, and who 
developed VAP later 
 
 
 
 Late VAP is more common than Early VAP. 
 Most common organism is Acinetobacter , followed by Pseudomonas and 
Klebsiella 
 Resistant organisms are more common than sensitive organisms, but this had no 
bearing on their outcomes. 
 APACHE III score at the time of the diagnosis of VAP is a good predictor of 
mortality, number of days of ICU and hospital stay 
 Modified CPIS score at the time of diagnosis of VAP is a predictor of the median 
survival in terms of ICU days 
 MODS score at the time of diagnosis of VAP is a predictor of mortality and the 
median survival in terms of ICU days 
 Age > 45 is a risk factor for mortality 
 Whether the ET aspirate culture grew a resistant organism or multiple organisms, 
did not have any significant effect on the outcome in terms of mortality, but 
polymicrobial infection will increase the ICU and the hospital stay. 
 Mortality is higher in those who develop late VAP. 
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 Acinetobacter infection had a better outcome in terms of total number of ICU days 
and hospital days , even if most of them were resistant to more than 3 groups of 
first line anti-microbial agents. 
                                         
 
 
 
                                          LIMITATION 
 
 As only the patients those who had normal chest x ray at the time of intubation 
was included in the study, the findings cannot be extrapolated to the entire VAP 
infection. 
 For the same reason incidence of VAP and per day risk of developing VAP could 
not be calculated based on this study 
 Not all patient had procalcitonin levels and there was no serial monitoring of 
procalcitonin done. The rate of decrease in Procalcitonin would have been a better 
predictor of outcome as seen in previous studies. 
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APPENDIX 1 
                                         PATIENT INFORMATION SHEET 
STUDY TITLE:- THE INCIDENCE, RISK FACTORS, CLINICAL AND MICROBIOLOGIC 
PROFILE AND PROGNOSTIC FACTORS OF VENTILATOR ASSOCIATED PNEUMONIA IN 
AN INDIAN TEACHING HOSPITAL SETTING. 
A clinical study is being conducted to evaluate the prevalence, risk factors, clinical 
and microbiological profile and prognostic factors of Ventilator Associated 
Pneumonia. This study involves collecting historical data regarding the patient’s 
illness, detailed clinical examination of the patient, collecting blood and ET 
aspirate/ bronchial lavage samples for laboratory tests, and following up the 
patient till discharge. 
Only those patients who develop features suggestive of pneumonia, 48 hours 
after the intubation are included in the study. The study requires no additional 
blood or any other tests, other than those which are done routinely for the 
evaluation and treatment of new onset pneumonia in intubated patients. The 
study incurs no additional cost to the participants in any manner. The study does 
not involve any invasive procedure on the patient, other than the collection of 
patient’s blood sample and the ET aspirate/ bronchial lavage samples. The patient 
will be followed up till the discharge. 
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The data collected from history, examination and investigations of the patient will 
be kept confidential, analyzed separately and results published in standard 
medical journals, without revealing the identity of the patient. 
The results anticipated from the study are expected to improve the 
understanding about the various aspects of Ventilator Associated Pneumonia, 
thereby guiding the treating physician in his/her approach towards the 
management of such cases. 
 
DATE: 
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APPENDIX 2 
 
 
                        INFORMED CONSENT FORM TO PARTICIPATE IN RESEARCH STUDY 
STUDY TITLE: THE INCIDENCE, RISK FACTORS, CLINICAL AND MICROBIOLOGIC 
PROFILE AND PROGNOSTIC FACTORS OF VENTILATOR ASSOCIATED PNEUMONIA IN 
AN INDIAN TEACHING HOSPITAL SETTING. 
NAME OF THE SUBJECT:                                                              AGE: 
HOSPITAL NUMBER:  
(i) I confirm that I have read and understood the information sheet dated _________ for the 
above study and have had the opportunity to ask questions. [ ] 
(ii) I understand that my participation in the study is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights being affected. [ ] 
(iii) I understand that the investigators of this research study, the Ethics Committee and the 
regulatory authorities will not need my permission to look at my health records both in respect 
of the current study and any further research that may be conducted in relation to it, even if I 
withdraw from the trial. I agree to this access. However, I understand that my identity will not 
be revealed in any information released to third parties or published. [ ] 
(iv) I agree not to restrict the use of any data or results that arise from this study provided such 
a use is only for scientific purpose(s) [ ] 
(v) I agree to take part in the above study. [ ] 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
Representative:_____________ 
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Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
 
Signature of the Witness: ___________________________ 
Date: ____/_____/_______ 
Name of the Witness: ______________________________ 
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APPENDIX 3 
 
                                    PROTOCOLS AND CRITERIAS USED 
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Modified CPIS Score- 
 
CPIS Points 0 1 2 
Tracheal secretions Rare Abundant Abundant＋purulent 
Chest X-ray infiltrates No infiltrate Diffused Localized 
Temperature, ℃ ≧36.5 and≦38.4 ≧38.5. 
and≦38.9 
≧39 or≦36 
Leukocytes count, per 
mm3 
≧4,000 
and≦11,000 
＜4,000 
or＞11,000 
＜4,000 or＞11,000＋ 
band forms≧500 
PAO2/FIO2, mmHg ＞240 or ARDS  ≦240 and no 
evidence of ARDS 
 
 
Pugin J, Auckenthaler R, Milli N, Janssens JP, Lew PD, Suter PM. Diagnosis of 
ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and 
nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis 
1991;143:1121-9 
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Multi Organ Dysfunction Score- 
 
 
 
 
 
Marshall JC, Cook DJ, Christou NV, et. al. Multiple organ dysfunction 
score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 
1995 Oct;23(10):1638-52. Review 
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APPENDIX 4 
                                  VENTILATOR ASSOCIATED PNEUMONIA 
Serial No:                  (MICU/MHDU/SICU/SHDU/AICU/KHDU) 
NAME:                                                                                            HOSP NO:                          
PLACE:                                                         AGE:                                                  SEX: (M=1,  F=2) 
DIAGNOSIS:                                                                                DOA:  Hospital-                                  ICU- 
HISTORY:                                                                                                              Medical/ surgical/ trauma                   
Intubation- Date:                                           Time:                            place:                  
Hours post-intubation , when clinical diagnosis of VAP is made-   
Tracheal Secretion- None/ Non-Purulent/ Purulent -  (  0  /  1  /  2 ) 
ORGAN FAILURE-     (No=0, Yes=1) 
Dyspnoea of NYHA grade-IV?    0   /  1                                        
On dialysis?    0  /  1 
Known case of hepatic failure/  liver cirrhosis/ Portal hypertension?    0  /  1 
On home Oxygen/ chronic hypoxia or hypercapnia / severe PAH/  polycythemia ?    0  /  1 
Any Immunosuppressive state?   0  /  1     (AIDS /  Lymphoma/  Leukemia/  metastatic cancer) 
Others- 
Non-operated /   post emergency operation/  post elective operation- 0  /   1   /   2 
CLINICAL:               MAP:                   CVP:                  HR:                 TEMP:                       RR:                       
GCS:     E                V                 M             =              /15                     Urine Output: 
ABG:      pH:                 A-a Gradient:                       FIO2:                       PAO2:                      PF Ratio: 
LAB:       Hematocrit:                       Platelets:                    WBC:                        Na:                    K:                   
Creatinine:                         Bilirubin:                   Urea:                   Glucose:                     Albumin: 
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 CHEST X-RAY-    No infiltrate/ Diffused or patchy/ Localized infiltrate-    (  0  /  1  /  2  ) 
MICROBIOLOGY:      ET Aspirate/ BAL Culture Report: 
 
PROGNOSTIC FACTORS:                             Mod.CPIS Score=                                         MOD Score=                           
 APACHE-II Score=                                                               Procalcitonin= 
OUTCOME:              Days of ICU stay=                                  Days of Hospital stay=     
FINAL OUTCOME-  Dead/ Alive      -    0  /   1                     DOD: 
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APPENDIX 5 
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